Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quantum Biopharma (QNTM) Current Deferred Revenue (2024 - 2025)

Quantum Biopharma's Current Deferred Revenue history spans 2 years, with the latest figure at -$1.0 million for Q2 2025.

  • On a quarterly basis, Current Deferred Revenue changed N/A to -$1.0 million in Q2 2025 year-over-year; TTM through Jun 2025 was -$1.0 million, a N/A change, with the full-year FY2024 number at $1.0 million, changed N/A from a year prior.
  • Current Deferred Revenue hit -$1.0 million in Q2 2025 for Quantum Biopharma, down from $1.0 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for QNTM hit a ceiling of $1.0 million in Q4 2024 and a floor of -$1.0 million in Q2 2025.